Learn how tirzepatide, a next‑generation dual GIP/GLP‑1 receptor agonist, uses advanced peptide engineering to deliver powerful glycemic control and bariatric‑level weight loss in type 2 diabetes, outperforming traditional GLP‑1 drugs.
Discover why tirzepatide is more than “another GLP‑1.” Learn how its dual GIP/GLP‑1 agonism, advanced peptide engineering, and once‑weekly dosing deliver deeper glucose control, powerful weight loss, and broad metabolic benefits compared to traditional GLP‑1 drugs.